Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute Inc. is making significant strides in developing therapies for rare and metabolic diseases, especially focusing on congenital hyperinsulinism, which presents a substantial market opportunity given the condition's unmet medical needs. The promising results from the Phase 2b RIZE study, which indicated a 70-90% reduction in weekly hypoglycemia events with their lead candidate, ersodetug, underscore the potential for improving patient outcomes and reducing treatment burdens. Continued favorable safety profiles and improvements observed in clinical trial patients enhance confidence in the company's pipeline, suggesting a robust path toward future revenue generation contingent upon successful product development and regulatory approval.

Bears say

Rezolute Inc's recent Phase 3 clinical trial results for its drug candidate, Ersodetug, revealed a failure to demonstrate a statistically significant benefit compared to placebo, leading to investor disappointment and concerns about the viability of its clinical programs. Additionally, the company's sunRIZE trial did not meet key secondary endpoints, further indicating potential challenges in efficacy and consistency in treatment outcomes. Coupled with the inherent regulatory uncertainties and the complexities of commercial markets, the outlook for Rezolute's stock appears negative as the company navigates these substantial risks and disappointing trial results.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.